At the level of individual MACE components, GLP-1 RAs also reduced CV mortality (by 13%, P = 0.016), nonfatal stroke (by 16%, P = 0.007), and nonfatal MI (by 9%, but statistically non-significant)
Target trial emulation: a framework for causal inference from observational data
[1] GLP-1s remain covered for: BMI 40 (Class III/morbid obesity) Type 2 Diabetes (Mounjaro, not Zepbound) Major Adverse Cardiac Events history Employers who opt-in to add weight loss drug coverage California Medi-Cal Alert: GLP-1 Exclusion Effective January 1, 2026 If you have Kaiser through Medi-Cal, weight loss GLP-1 coverage is ending
Cagrilintide (10mg vial) $199 Cagrilintide Peptide (10 mg vial) infusion from AMIV helps regulate appetite, support weight loss, and improve overall metabolic health
When to Speak with Your GP About GLP-1 and GIP It is important to have an open conversation with your GP before starting any supplement regimen, particularly if you are considering natural products to support metabolic health or blood glucose control